<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftolozane and tazobactam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftolozane and tazobactam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftolozane and tazobactam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="98776" href="/d/html/98776.html" rel="external">see "Ceftolozane and tazobactam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="138674" href="/d/html/138674.html" rel="external">see "Ceftolozane and tazobactam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26736432"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zerbaxa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871865"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zerbaxa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26643097"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cephalosporin Combination</li></ul></div>
<div class="block doa drugH1Div" id="F26841425"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Zerbaxa (ceftolozane/tazobactam) is a combination product. Dosage recommendations are expressed as grams of ceftolozane/tazobactam combination. Not recommended for routine empiric use. Reserve use for patients with or at risk for certain multidrug-resistant gram-negative organisms (eg, <i>P. aeruginosa</i> with difficult-to-treat resistance) with limited treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-33177185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-33177185'])">Ref</a></span>). When the 3 g dose is utilized for the treatment of multidrug-resistant gram-negative infections, it is recommended to extend infusion time (ie, over 3 hours instead of standard 1 hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative agent): IV:</b> 1.5 to 3 g every 8 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-24982069','lexi-content-ref-28085573','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-24982069','lexi-content-ref-28085573','lexi-content-ref-Manu.1'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated (alternative agent):</b>
<b>IV:</b> 3 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31563344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31563344'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67c92391-eee2-438d-87d4-7dc4f6150fa0">Serious infections due to multidrug-resistant <i>P. aeruginosa</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serious infections (eg, bloodstream infection, skin and soft tissue infection) due to multi</b>
<b>drug-resistant <i>P. aeruginosa</i></b>
<b>(off-label use):</b>
<b>IV:</b> 1.5 to 3 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27670678','lexi-content-ref-26935574','lexi-content-ref-Soliman.2015','lexi-content-ref-27999042','lexi-content-ref-27522066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27670678','lexi-content-ref-26935574','lexi-content-ref-Soliman.2015','lexi-content-ref-27999042','lexi-content-ref-27522066'])">Ref</a></span>); 3 g every 8 hours should be used for pulmonary infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Soliman.2015','lexi-content-ref-27522066','lexi-content-ref-26096377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Soliman.2015','lexi-content-ref-27522066','lexi-content-ref-26096377'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 g every 8 hours. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-35439291','lexi-content-ref-25931244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-35439291','lexi-content-ref-25931244'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991965"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Dosage recommendations are expressed as grams of ceftolozane/tazobactam combination.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Altered kidney function:</b> IV:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ceftolozane/Tazobactam Dose Adjustments for Kidney Impairment<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">CrCl<sup class="footnote-number">b</sup> (mL/minute)</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">If the usual recommended dose is 1.5 g every 8 hours</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">If the usual recommended dose is 3 g every 8 hours</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>Choose usual recommended dose based on indication and disease severity (see adult dosing), then choose the adjusted dose from that column corresponding to the patient's CrCl.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>CrCl may be estimated using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup>
<b>Note:</b> May consider delaying dosage adjustment (eg, administer full doses for 48 hours after initiation) before decreasing the dose for acute kidney injury (AKI). In a subgroup analysis of ceftolozane/tazobactam clinical trials, cure rates were lower in subjects with CrCl 30 to 50 mL/minute compared to subjects with CrCl &gt;50 mL/minute (Kullar 2017; Palchak 2015). It has been suggested that this may be due to underdosing of the medication at the beginning of treatment due to a falsely low estimate of CrCl based on an admission serum creatinine value. Elevated serum creatinine values quickly normalize in over half of patients thought to have AKI (Crass 2019).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&gt;50 to 130 (usual recommended dosing schedule)</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.5 g every 8 hours</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 g every 8 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">30 to 50</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">750 mg every 8 hours<sup class="footnote-number">c</sup></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.5 g every 8 hours<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 to 29</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">375 mg every 8 hours<sup class="footnote-number">c</sup></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">750 mg every 8 hours<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&lt;15 mL/minute not on dialysis</p></td>
<td align="center" colspan="2" valign="middle">
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>IV: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematological malignancies. A measured urinary clearance is necessary to identify these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Empiric therapy: Monte Carlo simulation suggests that a 1.5 g loading dose followed by 4.5 g continuous infusion over 24 hours will meet pharmacodynamic targets. If unable to administer by continuous infusion, the more aggressive intermittent dose (3 g every 8 hours) is preferred over the 1.5 g every 8-hour regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31358583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31358583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Directed therapy (pathogen is susceptible): 3 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31358583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31358583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> IV: Dialyzable (ceftolozane 66%; tazobactam 56%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24492369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24492369'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If the usual recommended dose is 1.5 g every 8 hours: </i>Initial: 750 mg as a single dose, followed by 150 mg every 8 hours. Administer dose immediately after dialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28013453','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28013453','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If the usual recommended dose is 3 g every 8 hours: </i>Initial: 2.25 g as a single dose, followed by 450 mg every 8 hours. Administer dose immediately after dialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28013453','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28013453','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations assume high-flux dialyzers and flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism minimum inhibitory concentration (MIC), residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: IV: 1.5 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27012450','lexi-content-ref-28237981','lexi-content-ref-31658965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27012450','lexi-content-ref-28237981','lexi-content-ref-31658965'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Monte Carlo simulation suggests that after 24 hours of therapy clinicians may consider reducing the dose to 750 mg every 8 hours to minimize accumulation at steady state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31658965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31658965'])">Ref</a></span>). Alternatively, these simulations also suggest that a 3 g loading dose followed by a maintenance dose of 750 mg every 8 hours will ensure adequate initial concentrations while minimizing accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31658965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31658965'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT:</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 750 mg loading dose, followed by 150 mg every 8 hours while off prolonged intermittent renal replacement therapy (PIRRT). For PIRRT sessions, give 750 mg at the start (within first hour) of PIRRT and an additional 750 mg within an hour after PIRRT session ends.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limited data available: Dosing based on a single case report describing a patient receiving PIRRT with blood and dialysate flow rates of 200 mL/minute for 7.5-hour treatments. Ceftolozane and tazobactam were extensively cleared by PIRRT; however, appropriate serum concentrations were maintained throughout the treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30304718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30304718'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989296"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F26841426"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F56826220"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="138674" href="/d/html/138674.html" rel="external">see "Ceftolozane and tazobactam: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Zerbaxa (ceftolozane and tazobactam) is a combination product; dosage recommendations are provided in mg of <b>ceftolozane</b>. Each 1.5 g vial of ceftolozane/tazobactam contains 1 g ceftolozane and 0.5 g tazobactam in a 2:1 ratio.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;18 years: IV: 20 mg ceftolozane/kg/dose every 8 hours in combination with metronidazole for 5 to 14 days; maximum dose: 1,000 mg ceftolozane per dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 1,000 mg ceftolozane every 8 hours in combination with metronidazole for 4 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated:</b> Adolescents ≥18 years: IV: 2,000 mg ceftolozane every 8 hours for 8 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;18 years: IV: 20 mg ceftolozane/kg/dose every 8 hours for 7 to 14 days; maximum dose: 1,000 mg ceftolozane per dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 1,000 mg ceftolozane every 8 hours for 7 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56826221"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Zerbaxa (ceftolozane and tazobactam) is a combination product; dosage recommendations are provided in mg of <b>ceftolozane</b>; use caution. Each 1.5 g vial of ceftolozane/tazobactam contains 1 g ceftolozane and 0.5 g tazobactam in a 2:1 ratio.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;18 years: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≤50 mL/minute/1.73 m<sup>2</sup>: Use is not recommended. Based on adult data, dosage adjustment is necessary, but pediatric-specific adjustments have not been determined.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: <b>Note:</b> Dosing recommendations are provided in terms of <b>ceftolozane</b> component.</p>
<p style="text-indent:-2em;margin-left:6em;">Intra-abdominal infection or complicated urinary tract infection: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 50 mL/minute: 500 mg ceftolozane every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 15 to 29 mL/minute: 250 mg ceftolozane every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hospital-acquired or ventilator-associated bacterial pneumonia: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 50 mL/minute: 1,000 mg ceftolozane every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 15 to 29 mL/minute: 500 mg ceftolozane every 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Dialyzable (ceftolozane: 66%; tazobactam: 56%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24492369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24492369'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;18 years: Use is not recommended. Based on adult data, dosage adjustment is necessary, but pediatric-specific adjustments have not been determined.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: <b>Note:</b> Dosing recommendations are provided in terms of ceftolozane component. IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Intra-abdominal infection or complicated urinary tract infection: Loading dose: 500 mg ceftolozane as a single dose, followed by 100 mg ceftolozane every 8 hours. Administer dose immediately after dialysis on dialysis days.</p>
<p style="text-indent:-2em;margin-left:6em;">Hospital-acquired or ventilator-associated bacterial pneumonia: Loading dose: 1,500 mg ceftolozane as a single dose, followed by 300 mg ceftolozane every 8 hours. Administer dose immediately after dialysis on dialysis days.</p></div>
<div class="block dohp drugH1Div" id="F56826224"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: IV: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F27106580"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults or pediatrics with complicated intra-abdominal infection (cIAI) and urinary tract infection (UTI) unless otherwise indicated for adults with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (neonates, infants, children, adolescents: 2% to 11%; adults: ≤1%), diarrhea (neonates, infants, children, adolescents: 7% to 17%; adults: cIAI, UTI: 2% to 6%, HAP, VAP: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive direct Coombs’ test (neonates, infants, children, adolescents: cIAI: 45%, UTI: 30%; adults: cIAI, UTI: &lt;1%, HAP, VAP: 31%) thrombocythemia (neonates, infants, children, adolescents: 9% to 16%; adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase: neonates, infants, children, adolescents: 4% to 7%; adults: cIAI, UTI: 1% to 2%, HAP, VAP: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (neonates, infants, children, adolescents: 7% to 13%; adults: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (adults: ≤1%), hypertension (neonates, infants, children, adolescents: 4%), hypotension (adults: ≤2%), phlebitis (neonates, infants, children, adolescents: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (neonates, infants, children, adolescents: 4%; adults: ≤3%), increased gamma-glutamyl transferase (adults: cIAI, UTI: &lt;1%, HAP, VAP: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (adults: HAP, VAP: 3%), constipation (adults: 2% to 4%), gastritis (neonates, infants, children, adolescents: 4%; adults: &lt;1%), nausea (adults: 3% to 8%), vomiting (neonates, infants, children, adolescents: 1% to 10%; adults: cIAI, UTI: 1% to 3%, HAP, VAP: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (neonates, infants, children, adolescents: 2% to 7%; adults: ≤2%), leukopenia (neonates, infants, children, adolescents: ≤8%), neutropenia (neonates, infants, children, adolescents: ≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (adults: cIAI, UTI: &lt;1%, HAP, VAP: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (adults: ≤2%), dizziness (adults: ≤1%), headache (adults: 3% to 6%), insomnia (adults: 1% to 4%), intracranial hemorrhage (adults: HAP, VAP: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (adults: cIAI, UTI: &lt;1%, HAP, VAP: ≤9%) renal insufficiency (adults: cIAI, UTIs: &lt;1%, HAP, VAP: ≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bradypnea (neonates, infants, children, adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1% (adults):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, tachycardia, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hypomagnesemia, hypophosphatemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, dyspepsia, flatulence, paralytic ileus</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Fungal urinary tract infection, vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction</p>
<p style="text-indent:0em;margin-left:2em;">Nervous system: Ischemic stroke</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, oropharyngeal candidiasis</p></div>
<div class="block coi drugH1Div" id="F26643052"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to ceftolozane/tazobactam, piperacillin/tazobactam, other members of the beta-lactam class, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F26841388"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity:  Hypersensitivity and anaphylaxis (serious and sometimes fatal) have been reported in patients receiving beta-lactam drugs.  Question patient about previous hypersensitivity reactions to other cephalosporins, penicillins or other beta-lactams. Cross-sensitivity has been established. If administered, use with caution and if anaphylaxis occurs, discontinue and institute appropriate supportive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment:  Exposure to ceftolozane is increased with increasing degrees of renal impairment; monitor creatinine clearance (CrCl) at least daily in patients with changing renal function and adjust the dose. In clinical trials, cure rates were lower in patients with a baseline CrCl of 30 to 50 mL/minute.</p></div>
<div class="block foc drugH1Div" id="F26736433"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zerbaxa: 1.5 g: Ceftolozane 1 g and tazobactam 0.5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F26736431"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26844487"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Zerbaxa Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 (1-0.5) g (per each): $190.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871866"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zerbaxa: 1.5 g: Ceftolozane 1 g and tazobactam 0.5 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F26841431"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer over 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); for the treatment of multidrug-resistant gram-negative organisms (eg, <i>P. aeruginosa</i> with difficult-to-treat resistance) and administration of 3 g doses, administer 3 g by IV infusion over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F56826226"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer over 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Consider administration over 3 hours if treating multidrug-resistant gram-negative bacteria or in adolescents receiving 2,000 mg ceftolozane per dose (3,000 mg ceftolozane/tazobactam) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F26643047"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Treatment of complicated intra-abdominal infection in adult and pediatric patients, in combination with metronidazole, caused by <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>Pseudomonas aeruginosa</i>, <i>Bacteroides fragilis</i>, <i>Streptococcus anginosus</i>, <i>Streptococcus constellatus</i>, and <i>Streptococcus salivarius</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-</b>
<b>acquired or ventilator-associated:</b> Treatment of hospital-acquired pneumonia and ventilator-associated bacterial pneumonia in patients ≥18 years of age, caused by <i>E. cloacae</i>, <i>E. coli</i>, <i>Haemophilus influenzae</i>, <i>K. oxytoca</i>, <i>K. pneumoniae</i>, <i>P</i>
<i>. mirabilis</i>, <i>P. aeruginosa</i>, and <i>Serratia</i>
<i>marcescens</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b> Treatment of complicated urinary tract infection, including pyelonephritis, in adult and pediatric patients caused by <i>E. coli</i>, <i>K. pneumoniae</i>, <i>P. mirabilis</i>, and <i>P. aeruginosa</i>.</p></div>
<div class="block off-label drugH1Div" id="F53308214"><span class="drugH1">Use: Off-Label: Adult</span><p>Serious infections due to multi-drug resistant Pseudomonas aeruginosa</p></div>
<div class="block cyt drugH1Div" id="F26736547"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F26736544"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Betalactamase Inhibitors. Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F26841385"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tazobactam crosses the placenta (Bourget 1998).</p>
<p style="text-indent:0em;margin-top:2em;">In general, an increased risk of major birth defects or other adverse fetal or maternal outcomes has not been observed following maternal use of cephalosporin antibiotics</p></div>
<div class="block brc drugH1Div" id="F26841387"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ceftolozane or tazobactam are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F26841430"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F26841433"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine and CrCl at baseline and daily in patients with changing renal function</p></div>
<div class="block pha drugH1Div" id="F26841414"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ceftolozane inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Ceftolozane is an inhibitor of PBPs of <i>Pseudomonas aeruginosa</i> (eg, PBP1b, PBP1c, and PBP3) and <i>Escherichia coli </i>(eg, PBP3). Tazobactam irreversibly inhibits some beta-lactamases (eg, certain penicillinases and cephalosporinases), and can covalently bind to some plasmid-mediated and chromosomal bacterial beta-lactamases.</p></div>
<div class="block phk drugH1Div" id="F26841416"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates and infants &lt;3 months (GA: ≤32 weeks): Geometric mean: Ceftolozane: 0.344 to 0.388 L/kg; Tazobactam: 0.338 to 0.667 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates and infants &lt;3 months (GA &gt;32 weeks): Geometric mean: Ceftolozane: 0.394 L/kg; Tazobactam: 0.668 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and children &lt;2 years: Geometric mean: Ceftolozane: 0.282 to 0.34 L/kg; Tazobactam: 0.421 to 0.574 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;7 years: Geometric mean: Ceftolozane: 0.312 to 0.331 L/kg; Tazobactam: 0.488 to 0.513 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to &lt;12 years: Geometric mean: Ceftolozane: 0.296 L/kg; Tazobactam: 0.74 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and adolescents &lt;18 years: Geometric mean: Ceftolozane: 0.274 L/kg; Tazobactam: 0.474 L/kg (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Ceftolozane: 13.5 L; Tazobactam: 18.2 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Ceftolozane: 16% to 21%; Tazobactam: 30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ceftolozane: Not metabolized; Tazobactam: Hydrolyzed to inactive metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and infants &lt;3 months: Ceftolozane: 2.7 ± 0.6 hours; Tazobactam: 1.2 ± 0.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and children &lt;2 years: Ceftolozane: 2 ± 0.7 hours; Tazobactam: 1.1 ± 0.4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;6 years: Mean range: Ceftolozane: 1.7 to 1.8 hours; Tazobactam: 1 ± 0.3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Mean range: Ceftolozane: 1.8 to 2 hours; Tazobactam: 1.1 to 1.2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and adolescents &lt;18 years: Mean range: Ceftolozane: 2.2 to 2.3 hours; Tazobactam: 1.3 ± 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Ceftolozane: ~3 to 4 hours; Tazobactam: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Ceftolozane: Urine (&gt;95% as unchanged drug); Tazobactam: urine (&gt;80% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51220825"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Renal clearance was similar to plasma clearance and to the GFR for the unbound fraction suggesting that ceftolozane is eliminated by glomerular filtration. The mean AUC of both ceftolozane and tazobactam increases with decreasing renal function in mild, moderate, and severe renal impairment. In patients with end-stage renal disease, tazobactam's elimination pathway through metabolism becomes clinically significant; recommended doses in this population are designed to optimize tazobactam's pharmacodynamic targets (Xiao 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Ceftolozane: time dependent, associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Gram-negative organisms (eg, <i>P. aeruginosa</i>): ceftolozane (in combination with tazobactam): goal: 35% <i>f</i>T &gt; MIC (1-log kill) (Craig 2013); ceftolozane (monotherapy): goal: ≥30% to 40% <i>f</i>T &gt; MIC (1- to 2-log kill) (Craig 2013; Lepak 2014).</p>
<p style="text-indent:-2em;margin-left:10em;">Gram-positive organisms (eg, <i>Streptococcus pneumoniae</i>): ceftolozane (monotherapy): goal: ≥27% <i>f</i>T &gt; MIC (2-log kill) (Lepak 2014).</p>
<p style="text-indent:-2em;margin-left:8em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:10em;">Critically ill patients in the ICU: minimum goal: ≥50% <i>f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Abdul-Aziz 2020; Al-Shaer 2020; Roberts 2014); some experts favor ≥100% <i>f</i>T &gt; 4 × MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Tazobactam (in combination with ceftolozane): time dependent, associated with <i>f</i>T &gt; threshold concentration, where threshold concentration is 0.5 × ceftolozane/tazobactam MIC.</p>
<p style="text-indent:-2em;margin-left:8em;">Gram-negative organisms: goal: ≥77% <i>f</i>T &gt; 0.5 × MIC (1-log kill); ≥90% <i>f</i>T &gt; 0.5 × MIC (2-log kill) (Vanscoy 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in healthy volunteers:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients: single dose (1-hour infusion): C<sub>max </sub>(peak): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Neonates and infants, GA: ≤32 weeks; PNA: 7 days to &lt;3 months: ceftolozane 20 mg/tazobactam 10 mg/kg: ceftolozane: 45.2 mg/L (range 33.3 to 61.2 mg/L); tazobactam: 12.1 mg/L (range: 6.43 to 22.7 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">Neonates and infants, GA: &gt;32 weeks; PNA: 7 days to &lt;3 months: ceftolozane 20 mg/tazobactam 10 mg/kg: ceftolozane: 45 mg/L (range: 36.3 to 55.9 mg/L); tazobactam: 11.7 mg/L (range: 7.48 to 18.3 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and children 3 months to &lt;2 years of age: ceftolozane 30 mg/tazobactam 15 mg/kg: ceftolozane: 91.3 mg/L (range: 72.1 to 116 mg/L); tazobactam: 22.4 mg/L (range: 13.8 to 36.6 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to &lt;7 years of age: ceftolozane 30 mg/tazobactam 15 mg/kg: ceftolozane: 96.6 mg/L (range: 71.2 to 131 mg/L); tazobactam: 24.8 mg/L (range: 13.2 to 46.6 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">Children 7 to &lt;12 years of age: ceftolozane 18 mg/tazobactam 9 mg/kg: ceftolozane: 56.2 mg/L (range: 45.3 to 69.7 mg/L); tazobactam: 9.25 mg/L (range: 5.92 to 14.5 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">Children and adolescents 12 to &lt;18 years of age: ceftolozane 1,000 mg/tazobactam 500 mg: ceftolozane: 63.5 mg/L (range: 50.2 to 80.4 mg/L); tazobactam: 14 mg/L (range: 8.59 to 22.9 mg/L) (Bradley 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: C<sub>max </sub>(peak): IV (1-hour infusion):</p>
<p style="text-indent:-2em;margin-left:10em;">Multiple doses (steady state):</p>
<p style="text-indent:-2em;margin-left:12em;">Ceftolozane 1 g/tazobactam 500 mg every 8 hours: ceftolozane: 65.7 ± 27 mg/L; tazobactam: 17.8 ± 9 mg/L (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:12em;">Ceftolozane 2 g/tazobactam 1 g every 8 hours: ceftolozane: 105 ± 46 mg/L; tazobactam: 26.4 ± 13 mg/L (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">Critically ill patients with augmented renal clearance: C<sub>max </sub>(peak): IV (1-hour infusion):</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: ceftolozane 2 g/tazobactam 1 g: ceftolozane: 73.9 ± 25.4 mg/L; tazobactam: 18.7 ± 6.95 mg/L (Nicolau 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>gram-negative organisms (eg, <i>E. coli</i>): ~0.8 hours (Sader 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Post–beta-lactamase-inhibitor effect:</i> gram-negative organisms (eg, <i>E. coli</i>): ~1.3 to 2.1 hours (Sader 2014).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939908"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zerbaxa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32910809">
<a name="32910809"></a>Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. <i>J Antimicrob Chemother.</i> 2020;75(12):3644-3651. doi:10.1093/jac/dkaa359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/32910809/pubmed" id="32910809" target="_blank">32910809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9481541">
<a name="9481541"></a>Bourget P, Sertin A, Lesne-Hulin A, Fernandez H, Ville Y, Van Peborgh P. Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination. <i>Eur J Obstet Gynecol Reprod Biol</i>. 1998;76(1):21-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/9481541/pubmed" id="9481541" target="_blank">9481541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30153232">
<a name="30153232"></a>Bradley JS, Ang JY, Arrieta AC, et al. Pharmacokinetics and safety of single intravenous doses of ceftolozane/tazobactam in children with proven or suspected gram-negative infection.<i> Pediatr Infect Dis J.</i> 2018;37(11):1130-1136. doi:10.1097/INF.0000000000002170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/30153232/pubmed" id="30153232" target="_blank">30153232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012450">
<a name="27012450"></a>Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/Tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. <i>Pharmacotherapy</i>. 2016;36(5):e30-e33. doi: 10.1002/phar.1744.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27012450/pubmed" id="27012450" target="_blank">27012450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28237981">
<a name="28237981"></a>Chaijamorn W, Shaw AR, Lewis SJ, Mueller BA. Ex vivo ceftolozane/tazobactam clearance during continuous renal replacement therapy.<i> Blood Purif.</i> 2017;44(1):16-23. doi: 10.1159/000455897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/28237981/pubmed" id="28237981" target="_blank">28237981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23274659">
<a name="23274659"></a>Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. <i>Antimicrob Agents Chemother.</i> 2013;57(4):1577-1582. doi:10.1128/AAC.01590-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/23274659/pubmed" id="23274659" target="_blank">23274659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30219824">
<a name="30219824"></a>Crass RL, Rodvold KA, Mueller BA, Pai MP. Renal dosing of antibiotics: are we jumping the gun? <i>Clin Infect Dis.</i> 2019;68(9):1596-1602. doi: 10.1093/cid/ciy790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/30219824/pubmed" id="30219824" target="_blank">30219824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care.</i> 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-120. doi: 10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27670678">
<a name="27670678"></a>Hernández-Tejedor A, Merino-Vega CD, Martín-Vivas A, et al. Successful treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> breakthrough bacteremia with ceftolozane/tazobactam. <i>Infection</i>. 2017;45(1):115-117. doi: 10.1007/s15010-016-0944-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27670678/pubmed" id="27670678" target="_blank">27670678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Hooton, TM. Acute complicated urinary tract infection (including pyelonephritis) in adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published corrections appear in <i>Clin Infect Dis</i>. 2017;64(9):1298; <i>Clin Infect Dis</i>. 2017;65(8):1435; <i>Clin Infect Dis</i>. 2017;65(12):2161]. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31563344">
<a name="31563344"></a>Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. <i>Lancet Infect Dis</i>. 2019;19(12):1299-1311. doi:10.1016/S1473-3099(19)30403-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/31563344/pubmed" id="31563344" target="_blank">31563344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999024">
<a name="27999024"></a>Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. <i>J Antimicrob Chemother.</i> 2017;72(3):900-905. doi:10.1093/jac/dkw486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27999024/pubmed" id="27999024" target="_blank">27999024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092700">
<a name="25092700"></a>Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. Impact of MIC range for <i>Pseudomonas aeruginosa</i> and <i>Streptococcus pneumoniae</i> on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. <i>Antimicrob Agents Chemother</i>. 2014;58(10):6311-6314. doi:10.1128/AAC.03572-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/25092700/pubmed" id="25092700" target="_blank">25092700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982069">
<a name="24982069"></a>Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. <i>Antimicrob Agents Chemother</i>. 2014;58(9):5350-5357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/24982069/pubmed" id="24982069" target="_blank">24982069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793988">
<a name="21793988"></a>Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. <i>Clin Microbiol Infect</i>. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/21793988/pubmed" id="21793988" target="_blank">21793988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33567333">
<a name="33567333"></a>Nicolau DP, De Waele J, Kuti JL, et al. Pharmacokinetics and pharmacodynamics of ceftolozane/tazobactam in critically ill patients with augmented renal clearance. <i>Int J Antimicrob Agents.</i> 2021;57(4):106299. doi:10.1016/j.ijantimicag.2021.106299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/33567333/pubmed" id="33567333" target="_blank">33567333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Palchak.2015">
<a name="Palchak.2015"></a>Palchak M, Popejoy M, Miller B. Outcomes of ceftolozane/tazobactam (C/T) in patients with moderate renal impairment in two phase 3 trials for the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI). <i>Open Forum Infectious Diseases</i>. 2015;2(suppl 1):901. doi:10.1093/ofid/ofv133.617</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26935574">
<a name="26935574"></a>Patel UC, Nicolau DP, Sabzwari RK. Successful treatment of multi-drug resistant pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane/tazobactam regimen. <i>Infect Dis Ther</i>. 2016;5(1):73-79. doi:10.1007/s40121-016-0104-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/26935574/pubmed" id="26935574" target="_blank">26935574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30304718">
<a name="30304718"></a>Rawlins M, Cheng V, Raby E, et al. Pharmacokinetics of ceftolozane-tazobactam during prolonged intermittent renal replacement therapy. <i>Chemotherapy</i>. 2018;63(4):203-206. doi: 10.1159/000493196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/30304718/pubmed" id="30304718" target="_blank">30304718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis.</i> 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24449780">
<a name="24449780"></a>Sader HS, Rhomberg PR, Jones RN. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains. <i>Antimicrob Agents Chemother.</i> 2014;58(4):2434-2437. doi:10.1128/AAC.02398-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/24449780/pubmed" id="24449780" target="_blank">24449780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31658965">
<a name="31658965"></a>Sime FB, Lassig-Smith M, Starr T, et al. A population pharmacokinetic model-guided evaluation of ceftolozane/tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.<i> Antimicrob Agents Chemother.</i> 2019b. pii: AAC.01655-19. doi: 10.1128/AAC.01655-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/31658965/pubmed" id="31658965" target="_blank">31658965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31358583">
<a name="31358583"></a>Sime FB, Lassig-Smith M, Starr T, et al. Population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal dysfunction. <i>Antimicrob Agents Chemother.</i> 2019a;63(10). pii: e01265-19. doi: 10.1128/AAC.01265-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/31358583/pubmed" id="31358583" target="_blank">31358583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Soliman.2015">
<a name="Soliman.2015"></a>Soliman R, Lynch S, Meade E, et al. Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan-resistant <i>Pseudomonas aeruginosa. </i>
<i>JMM</i>. 2015;1-doi: 4. 0.1099/jmmcr.0.000025.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25670823">
<a name="25670823"></a>Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). <i>Clin Infect Dis</i>. 2015;60(10):1462-1471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/25670823/pubmed" id="25670823" target="_blank">25670823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20163262">
<a name="20163262"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Surg Infect (Larchmt)</i>. 2010;11(1):79-109. doi: 10.1089/sur.2009.9930.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/20163262/pubmed" id="20163262" target="_blank">20163262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999042">
<a name="27999042"></a>Sousa Dominguez A, Perez-Rodríguez MT, Nodar A, Martinez-Lamas L, Perez-Landeiro A, Crespo Casal M. Successful treatment of MDR <i>Pseudomonas aeruginosa</i> skin and soft-tissue infection with ceftolozane/tazobactam. <i>J Antimicrob Chemother</i>. 2017;72(4):1262-1263. doi:10.1093/jac/dkw526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27999042/pubmed" id="27999042" target="_blank">27999042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with difficult-to-treat resistance (DTR-<i>P. aeruginosa</i>). <i>Clin Infect Dis</i>. 2022;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24041895">
<a name="24041895"></a>Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. <i>Antimicrob Agents Chemother</i>. 2013;57(12):5924-5930. doi:10.1128/AAC.00656-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/24041895/pubmed" id="24041895" target="_blank">24041895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27522066">
<a name="27522066"></a>Vickery SB, McClain D, Wargo KA. Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Pharmacotherapy</i>. 2016;36(10):e154-e159. doi: 10.1002/phar.1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/27522066/pubmed" id="27522066" target="_blank">27522066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25931244">
<a name="25931244"></a>Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). <i>Lancet</i>. 2015;385(9981):1949-1956. doi:10.1016/S0140-6736(14)62220-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/25931244/pubmed" id="25931244" target="_blank">25931244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492369">
<a name="24492369"></a>Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. <i>Antimicrob Agents Chemother</i>. 2014;58(4):2249-2255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/24492369/pubmed" id="24492369" target="_blank">24492369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28013453">
<a name="28013453"></a>Xiao AJ, Caro L, Popejoy MW, Huntington JA, Kullar R. PK/PD target attainment with ceftolozane/tazobactam using monte carlo simulation in patients with various degrees of renal function, including augmented renal clearance and end-stage renal disease.<i> Infect Dis Ther.</i> 2017;6(1):137-148. doi: 10.1007/s40121-016-0143-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/28013453/pubmed" id="28013453" target="_blank">28013453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096377">
<a name="26096377"></a>Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. <i>J Clin Pharmacol</i>. 2016;56(1):56-66. doi: 10.1002/jcph.566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/26096377/pubmed" id="26096377" target="_blank">26096377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33177185">
<a name="33177185"></a>Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. <i>Clin Microbiol Rev</i>. 2020;34(1):e00115-e00120. doi:10.1128/CMR.00115-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftolozane-and-tazobactam-drug-information/abstract-text/33177185/pubmed" id="33177185" target="_blank">33177185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zerbaxa.1">
<a name="Zerbaxa.1"></a>Zerbaxa (ceftolozane/tazobactam) [prescribing information]. Syracuse, NY: Steri-Pharma LLC; May 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 98763 Version 141.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
